- Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
-
Yang K, Chen Y, To KK, Wang F, Li D, Chen L, Fu L
- KMID: 2375790
- Exp Mol Med.
- 2017 Mar;49(3):e303.
- doi: 10.1038/emm.2016.168
Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). Here... -
- CITED
-
- Close
- SHARE
-
- Close
